

# Administrative Bulletin 20-06

**101 CMR 320.00 Clinical Laboratory Services**

Effective January 1, 2020

**Procedure Code Update**

Pursuant to 101 CMR 320.01(3), the Executive Office of Health and Human Services is adding new procedure codes for clinical laboratory services. As set forth in 101 CMR 320.01(3)(c), the rates for newly added codes are calculated according to the rate methodology used in setting clinical laboratory rates. Added codes without Medicare fees are reimbursed at individual consideration (I.C.). Rates listed in this administrative bulletin are applicable until revised rates are issued by the EOHHS.

The changes, effective January 1, 2020, are as follows.

| **CODE** | **CHANGE** | **RATE** | **DESCRIPTION**  |
| --- | --- | --- | --- |
| 80145 | Addition | $28.50 | Adalimumab |
| 80187 | Addition | $20.03 | Posaconazole |
| 80230 | Addition | $28.50 | Infliximab |
| 80235 | Addition | $20.03 | Lacosamide |
| 80280 | Addition | $28.50 | Vedolizumab |
| 80285 | Addition | $20.03 | Voriconazole |
| 81277 | Addition | $857.12 | Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities |
| 81307 | Addition | $209.02 | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence |
| 81308 | Addition | $222.67 | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant |
| 81309 | Addition | $203.07 | PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20) |
| 81522 | Addition | $2,861.76 | Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score |
| 81542 | Addition | I.C. | Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score |
| 81552 | Addition | I.C. | Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis |
| 87563 | Addition | $25.93 | Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique |